



## CLINICAL GUIDELINE

# Atopic Eczema in Children

A guideline is intended to assist healthcare professionals in the choice of disease-specific treatments.

Clinical judgement should be exercised on the applicability of any guideline, influenced by individual patient characteristics. Clinicians should be mindful of the potential for harmful polypharmacy and increased susceptibility to adverse drug reactions in patients with multiple morbidities or frailty.


If, after discussion with the patient or carer, there are good reasons for not following a guideline, it is good practice to record these and communicate them to others involved in the care of the patient.

<b>Original Date of Approval:</b>	10/04/2015
<b>Date of Update:</b>	25/04/2017
<b>Review Date:</b>	25/04/2019
<b>Lead Author:</b>	Dr Paula Beattie
<b>Approval Group:</b>	Paediatric Clinical Effectiveness & Risk Committee
<b>Clinical Content Changes (Y/N):</b>	N
<b>CGSU Version no:</b>	2

# Guidance For Management of Atopic Eczema

Dermatology Dept. RHSC Glasgow

For further advice see <http://www.sign.ac.uk/pdf/sign125.pdf>  
<http://www.18weeks.scot.nhs.uk/patient-pathways/dermatology/>



If weeping/crusted: swab then use Betnovate C®/Synalar C® or Trimovate® depending on body site

**If not controlled with above Management then refer to Dermatology**

Guidance for Management of Atopic Eczema	Version: 1.1	Page 1 of 1
Author: Paula Beattie	Authorised by:	Issue Date:
Last reviewed: Mar 2015	Q-Pulse Ref: YOR-AE-005	Review date: Apr 2019